Thus, the concurrent increase in Mfsd2a expression and reduction in Aqp4 expression following the high-dose FO supplementation resulting in the decreased blood vessels Aβ accretion in the retina indicates the strong potential of the FO as an adjuvant therapy in the presymptomatic phase of AD or other amyloid-based diseases. Here, AQP4 is linked to Alzheimer disease.